Neuroendocrine neoplasms of the small intestine and appendix — management guidelines (recommended by the Polish Network of Neuroendocrine Tumours)


1Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Poland
2Department of Endocrinology, Diabetology, and Isotope Therapy, Wroclaw Medical University, Poland
3Department of Endocrinology and Neuroendocrine Tumours, Medical University of Silesia, Katowice, Poland
4Chair and Department of Endocrinology, Jagiellonian University, Medical College, Krakow, Poland
5Department of Oncology and Radiotherapy, Medical University of Silesia, Katowice, Poland
6Department of Oncological Surgery, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland
7Department of Radiology, Faculty of Medical Sciences, University of Warmia and Mazury, Olsztyn, Poland
8Pancreas Translational & Clinical Research Center, Università Vita e Salute, Milano (Italy)
9Department of Endocrinology and Neuroendocrine Tumours, Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland
10Department of Nuclear Medicine and Endocrine Oncology, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice Branch, Poland
11Chair and Department of Endocrinology and Diabetology, Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz, Poland
12Division of Pathophysiology, Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland
13Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine, Warsaw, Poland
14Department of Clinical Oncology, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland
15Endocrinology Clinic of Holy Cross Cancer Centre, Kielce, Poland
16Department of General Vascular and Transplant Surgery, Medical University of Silesia, Katowice, Poland
17Nuclear Medicine Department, Medical University of Warsaw, Poland
18Department of Gastrointestinal Surgery, Medical University of Silesia, Katowice, Poland
19Department of Tumour Pathology, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice Branch, Poland
20Department of Endocrinology and Internal Diseases, Medical University of Gdansk, Poland
21Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Poland
22Department of Gastroenterology, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland
23Department of Pathology, The Jan Kochanowski University, Kielce, Poland
24Department of Gastroenterology and Hepatology, Medical University of Silesia, Katowice, Poland
25Department of Radiology, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland
26Department of Radiology and Nuclear Medicine, Medical University of Silesia, Katowice, Poland
27Department and Clinic of Endocrinology, Metabolism and Internal Diseases, University of Medical Sciences, Poznan, Poland
28Department of Gastroenterology, Pomeranian Medical University, Szczecin, Poland
29Department of Endocrinology, Metabolic and Internal Diseases, Pomeranian Medical University, Szczecin
30Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland
31Department of Colorectal, General, and Oncological Surgery, Centre of Postgraduate Medical Education, Warsaw, Poland
32Department of Endocrinology, Postgraduate Medical Education Centre, Warsaw, Poland

*co-first authors
**other authors arranged in alphabetical order
***senior author

Endokrynologia Polska
DOI: 10.5603/EP.2017.0018
Tom/Volume 68; Numer/Number 2/2017
ISSN 0423–104X

223
Abstract

This study presents the revised Polish guidelines regarding the management of patients suffering from neuroendocrine neoplasms (NENs) of the small intestine and appendix. The small intestine, especially the ileum, is the most common location for these neoplasms. Most are well differentiated and slow growing. Their symptoms may be atypical, which can result in delayed or accidental diagnosis. Appendicitis is usually the first manifestation of NEN in this location. Typical symptoms of carcinoid syndrome occur in approximately 20–30% of patients suffering from small intestinal NENs with distant metastases. The main cause of death in patients with carcinoid syndrome is carcinoid heart disease. The most useful laboratory test is the determination of chromogranin A, while concentration of 5-hydroxyindoleacetic acid is helpful in the diagnostics of carcinoid syndrome. For visualisation, ultrasound, computed tomography, magnetic resonance imaging, colonoscopy, video capsule endoscopy, double-balloon enteroscopy, and somatostatin receptor scintigraphy may be used. A detailed histological report is crucial for the proper diagnostics and therapy of NENs of the small intestine and appendix. The treatment of choice is surgical management, either radical or palliative. The pharmacological treatment of the hormonally active and non-active small intestinal NENs as well as NENs of the appendix is based on long-acting somatostatin analogues. In patients with generalised NENs of the small intestine in progress during the SSA treatment, with good expression of somatostatin receptors, the first-line treatment should be radioisotope therapy, while targeted therapies, such as everolimus, should be considered afterwards. When the above therapies are exhausted, in certain cases chemotherapy may be considered. (Endokrynol Pol 2017; 68 (2): 223–236)

Key words: neuroendocrine neoplasms; guidelines; small intestine; appendix; carcinoid syndrome; somatostatin analogues; PRRT, radioisotope therapy; everolimus

Introduction

Neuroendocrine neoplasms (NEN) of the small intestine originate in the midgut, with the small intestine being the third most common site of their occurrence, after the pancreas and large intestine. From the clinical point of view, we distinguish between hormonally active and non-active NENs. Hormonally active NENs secrete substances that cause the characteristic symptoms known as carcinoid syndrome. Most small intestinal NENs are well differentiated and grow slowly. Rarely, they may be poorly differentiated, with rapid growth and a poor prognosis. However, small intestinal NENs are often diagnosed in the generalised stage with distant metastases. Tumours in this location are very rarely part of MEN 1 syndrome [1–4].

Neuroendocrine neoplasms of the end part of the small intestine and the appendix are mostly composed of EC (enterochromaffin) cells, responsible for serotonin production. Certain NENs demonstrate the ability to secrete enteroglucagon, glucagon, or other peptides. It is believed that ileum NENs are more aggressive than the neuroendocrine tumours of the duodenum, tumours of the stomach built of ECL (enterochromaffin-like) cells, or tumours of the rectum. They demonstrate a higher metastatic ability, associated to a lesser degree with the size of the tumour [1–3].

1. Epidemiology

The small intestine, particularly the ileum, is the most common site of NENs in the human body. Small intestinal NENs occur equally often in male and female patients; they affect all age groups, with the peak in the 6th and 7th decades of life. The estimated prevalence is 0.32–1.12 per 100,000 of the population per year, including malignancy in 0.29 per 100,000. Apart from the small intestine, they also affect the appendix [3, 5–11]. In post-mortem examinations the reported prevalence increases to 1.22% [3, 12]. Tumours originating from the lower part of the jejunum and the ileum constitute 23–38% of all gastro-entero-pancreatic endocrine neoplasms, and they are more common than endocrine neoplasms of the appendix, also described in paediatric patients [3, 13, 14]. Hormonally active neuroendocrine neoplasms of the small intestine are often multifocal, and in 15% of cases are associated with other neoplasms such as gastrointestinal adenocarcinoma or breast cancer [3].

The term carcinoid is still associated with a certain ambiguity. In the past, the term referred to a neuroendocrine neoplasm, regardless of the location of the primary tumour site or the level of malignancy. Later, in Europe, carcinoids were limited to neoplasms originating from the midgut, secreting serotonin and associated with carcinoid syndrome symptoms. However, the World Health Organisation (WHO) 2010 classification of the gastro-entero-pancreatic neuroendocrine neoplasms attributed the term carcinoid to G1 neuroendocrine neoplasms. The Polish Network of Neuroendocrine ‘Tumours argues that the term ‘carci-noid’ should be relinquished, and substituted with the name ‘neuroendocrine tumour’ or ‘neuroendocrine neoplasm’ [2, 3, 5, 15, 16].

Over the last 30 years, the incidence of neuroendocrine neoplasms of the gastrointestinal tract has increased by 720%, and of the small intestine by 460%. In this period there has also been an increase in the ileum neuroendocrine neoplasm rate within the small intestine, from 52% to 63.6%. This is very important because neoplasms are malignant in this area in 58% of cases, whereas this group of tumours constitutes no more than 35% of cases within the whole small intestine. A higher prevalence has been observed in African-Americans
and in females, compared to Caucasians and males. Although the increase in the diagnosis of gastric and rectal NENs can be partially explained by the development of endoscopic techniques, such an explanation does not apply to the higher incidence of small intestinal NENs [2, 3, 5, 17, 18]. According to experts from the Polish Network of Neuroendocrine Tumours, endoscopic tests of the large intestine, including screening colonoscopy (over a 20-year period) increased the detection of small intestinal NENs. The person performing colonoscopy in most cases assesses not only the large intestine, but also the terminal part of the small intestine, where small intestinal NENs are found most frequently [19, 20].

Most tumours are located in the terminal part of the ileum, in close proximity to the ileocecal valve. They often involve metastases to the regional lymph nodes, and then to the liver. The prognosis in these cases is usually poor and depends on the TNM staging assessment and Ki-67 grading [3, 16]. The five-year survival rate is 100% for patients with stages I and II small intestinal NENs, 97.1% for patients with stage III, and 84.8% for patients with stage IV. Based on the level of tumour differentiation, the five-year survival rate is 93.8% for G1, 83% for G2, and 50% for G3 [3, 21]. Other studies have reported the five-year survival rate to be 72% in patients with local tumours, and 55% in patients with distant metastases [3, 22]. According to alternative European data, the five-year survival rate is 59–74% in patients with NENs of the small intestine and appendix [3, 9, 23]. Previous observations demonstrated a ten-year survival rate of 60% in patients without liver metastases at the diagnosis, and 15–25% in metastatic patients. Multifactorial analyses suggest that tumour metastases to the lymph nodes, hepatic involvement, and distant metastases outside the abdominal cavity are independently related to the survival rates. Moreover, the prognosis may improve if the primary tumour is removed [3].

2. Clinical characteristics

2.1. Symptoms of the hormonally active NETs of the small intestine — carcinoid syndrome

Carcinoid syndrome occurs in approximately 20–30% of patients suffering from small intestinal NETs with distant metastases. Carcinoid syndrome comprises symptoms resulting from an excessive secretion of serotonin and other biologically active compounds by the tumour (including kinins, prostaglandins, and histamine). Serotonin secreted to the portal venous system is metabolised in the liver and does not cause any clinical symptoms. The symptoms occur if serotonin and other biogenic amines are secreted directly to the systemic circulation; therefore, the carcinoid syndrome symptoms occur most often with hepatic metastases from NETs (approximately 95% of cases) [1,3].

Clinical symptoms of carcinoid syndrome include:
(a) symptoms affecting the skin (flushing, telangiectasis, pellagra — skin inflammation caused by vitamin PP deficiency, resulting from the use of tryptophan for excessive serotonin production by the neoplasm);
(b) symptoms affecting the gastrointestinal tract (secretory diarrhoea, non-specific or colic abdominal pains);
(c) symptoms affecting the cardiovascular system (tricuspid valve disorders, diseases of the pulmonary trunk, rarely mitral valve and aorta disorders);
(d) symptoms affecting the respiratory system (bronchial asthma); and e) symptoms affecting the musculoskeletal system (osteoarticular pains, myopathies) [5, 24]. Carcinoid syndrome significantly reduces the quality of life in patients with small intestinal NETs [25].

Flushing is one of the main symptoms of carcinoid syndrome (60–85% of patients). The flushing that accompanies serotonin secreting NETs of the small intestine (classical carcinoid syndrome) is pale-pink to red, affecting the face and upper chest, and lasting up to 30 minutes. Triggering factors include alcohol, spicy foods, emotional stress, and medications (serotonin reuptake inhibitors). Flushing in the case of foregut NETs (atypical form of carcinoid syndrome) is more intensive, with a crimson shade, and lasts longer (as long as several days) [3, 26].

The main causes of death in patients with carcinoid syndrome are heart diseases — referred to as carcinoid heart disease (CHD) or Hedinger’s syndrome, which may affect 25–50% of patients. CHD is mainly characterised by plaques of fibrous tissue on the valves of the right heart, leading to tricuspid valve regurgitation/stenosis (the most common defect) and stenosis/regurgitation of the pulmonary valve. Initially the clinical symptoms of CHD are weakly pronounced; later the symptoms of right ventricular heart failure progress. The prognosis for patients with CHD and severe heart failure (NYHA classes III and IV) is unfavourable; the median survival rate for patients without cardiac surgical treatment is 11 months. The gold standard in CHD diagnosis is echocardiography, which should be performed in all patients with carcinoid syndrome. Possible NET metastases to the pericardium should also be considered [3, 27–29].

Carcinoid crisis is a rare, life-threatening complication caused by a sudden release of biologically active substances to the systemic circulation. The symptoms include: prolonged skin redness, intense diarrhoea or vomiting, wheezing, blood pressure fluctuations, arrhythmia, disturbed nervous system function, dehydration, shock, acute renal failure, or hypercalcæmia. The crisis may occur independently, during infection, or as a result of medical procedures: general anaesthesia, endoscopy, tumour biopsy, surgery, embolisation, radioisotope therapy,
or chemotherapy [3, 30]. Therefore, it is recommended that somatostatin analogues are used in the pre-operative period or during surgery on NEN patients [3].

2.2. Symptoms of hormonally non-active NENs of the small intestine
The clinical picture of hormonally non-active NENs of the small intestine relates to the local symptoms. Small tumours are usually asymptomatic; they are found while identifying the source of metastases, or accidentally during colonoscopy in the ileocaecal region. Larger tumours, of more than 1 cm, are usually malignant and metastatic. The most common symptoms reported by patients are non-specific and include transient abdominal pains and discomfort (lasting for years, and often misinterpreted as irritable bowel syndrome), weight loss, and weakness. Over time, the symptoms worsen and may result in transient obstructions of the small intestine caused by the presence of the tumour mass, or by the desmoplastic reaction of the mesentery. Moreover, the desmoplastic reaction can impair the blood supply in the intestines, in severe cases leading to necrosis. A desmoplastic reaction rarely results in retroperitoneal fibrosis or hydrenephrosis. Severe gastrointestinal bleeding is a rare symptom of small intestine NENs [3, 4, 31].

2.3. Symptoms of NENs of the appendix (aNENs)
Appendicitis is usually the first manifestation of carcinoid in this location. Over half of the neuroendocrine neoplasms of the appendix are discovered accidentally following appendectomy. Most NENs of the appendix are diagnosed at the early stages. This contributes to a high survival rate in patients with tumours in this location, which is particularly visible in children, where over 80% of the diagnosed tumours are smaller than 1 cm. The size of the tumour is of crucial importance for the occurrence of metastases: for tumours smaller than 1 cm in diameter, metastases occur in 2%; for tumours of 1–2 cm in diameter, it is 50%; and for tumours larger than 2 cm, it is 80–90% of patients [3, 32]. Based on the data analysis from the SEER database, 10-year survival was observed in 100% of aNEN patients without lymph node metastases, and over 90% in metastatic patients, regardless of the size of the original tumour [33].

3. Diagnostics

3.1. Laboratory diagnostics
In the biochemical diagnostics of NEN of the small intestine and appendix, it is useful to determine the concentration of chromogranin A (CgA) — a sensitive although not highly specific marker (the determination and interpretation of results are described in the section on general diagnostics of gastro-entero-pancreatic neuroendocrine tumours). A significantly increased CgA concentration may be treated as an indicator of poor prognosis [3, 34–36].

The assessment of 5-hydroxyindoleacetic acid (5-HIAA) excretion in urine is a sensitive tumour indicator, useful for the diagnosis and monitoring of disease progression or treatment in patients with carcinoid syndrome. The sensitivity and specificity of 5-HIAA determination in order to confirm carcinoid syndrome are 70–100% and 85–90%, respectively [3]. The determination of blood serotonin levels is not presently recommended in the diagnostics of carcinoid syndrome [34, 37].

In the diagnostics and assessment of the severity of carcinoid heart disease, the determination of 5-HIAA and NT-proBNP (N-terminal-pro-B-type natriuretic peptide) may be useful [3, 34, 38].

Tests on the use of new biomarkers indicate that molecular tests could be used in the diagnostics and monitoring of NENs. Once validated, they would most probably be implemented in clinical practice [39, 40].

Minimal consensus statement on biochemical tests:
— CgA and 5-HIAA in all patients diagnosed with NEN of the small intestine before treatment and during monitoring (*evidence level 3);
— 5-HIAA — in patients with suspected carcinoid syndrome (*evidence level 3);
— NT-proBNP — in the case of carcinoid heart disease (*evidence level 4).

3.2. Imaging and endoscopic diagnostics

3.2.1 Primary tumour location
The diagnostics of small intestine diseases may include computed tomography (CT) enterography/enteroclysis or magnetic resonance imaging (MRI) enterography/enteroclysis, which locate the primary focus in the small intestine in approximately 90–97% of patients [41–43]. For the follow-up concerning small intestine diseases, CT or MRI enterography should be applied. MRI enteroclysis should be performed in patients with a clinically suspected pathology of the small intestine and with negative MRI/CT enterography results [3, 5, 44, 45].

Ultrasonography (US) is of limited use in detecting the primary tumour site. It is a subjective test, where the results depend on the quality of the equipment. In individual cases a transabdominal US of the small intestine, using high frequency probes, may enable the detection of the primary tumour site. However, possible secondary lesions in the mesentery should be consid-
ered, such as enlarged, hypoechogenic lymph nodes, or fibrosis/thickening of the mesentery, which may be more visible than a small primary tumour site hidden in the intestinal wall. It may be of use in the preliminary diagnostics of patients with suspected NENs [46].

Endoscopic diagnostics of the small intestine is usually undertaken to identify the primary tumour site in the case of metastases of unknown origin (often significantly larger than the primary tumour), in the case of non-specific abdominal symptoms, or to find the cause of gastrointestinal bleeding [3, 47]. The common use of colonoscopy, including screening colonoscopy, enables early detection of small intestinal lesions. The direct presentation of a NEN located in the small intestine is possible during a colonoscopy, when the tumour protrudes through the ileocaecal valve into the caecum lumen (such cases are very rare), but primarily takes place during routine assessment of the distal section of the small intestine. Colonoscopy is also important to exclude a concomitant neoplastic disease, and it enables endoscopic treatment [48]. Endoscopic ultrasonography (EUS), unlike for other locations of GEP NEN lesions, is of no use in the diagnostics of small intestine tumours [3].

Video capsule endoscopy (VCE) and balloon or spiral enteroscopy can be used for direct assessment of the jejunum and ileum mucosa, but these methods are not commonly used. A complete assessment of the small intestine is achieved in approximately 80% of patients, and the overall diagnostic efficiency of the test is about 55% [3, 49–53]. VCE sensitivity in the diagnosis of neuroendocrine tumours is relatively low, and compared to CT enterography is 29–37.5% vs. 50–92% [3, 54]. It is worth emphasising that neuroendocrine neoplasms of the small intestine, due to secreted growth factors resulting in desmoplastic reactions of the mesentery, often cause significant narrowing of the intestine, which is an absolute contraindication for video capsule endoscopy, because of the risk of capsule incarceration [55]. Another disadvantage of VCE is the inability to locate the tumour precisely [3, 56–58]. Balloon enteroscopy or spiral enteroscopy are not associated with this shortcoming, but their diagnostic efficiency is not very high [3, 59–62]. Enteroscopy enables not only the detection of small intestinal lesions, but also of endoscopic treatment [63].

Radioisotope diagnostics with the use of radioisotope-labelled somatostatin analogues (somatostatin receptor imaging, SRI) is a more sensitive method than radiological tests. The sensitivity of SRI is approximately 80% for the identification of the primary tumour site [64, 65]. Examinations using positron tracers (e.g. ⁶⁷Ga) are the preferred imaging method, particularly if the lesions are < 1 cm [66]. To locate the primary tumour site and assess the disease stage, SRI in correlation with multiphase CT/MRI is recommended. In the case of incomplete surgery of the NEN of the appendix or if distant metastases are suspected, SRI should be performed [67].

3.2.2. Evaluation of the stage of advancement and response to treatment

Multiphase, mostly three-phase, CT or MRI examinations after intravenous administration of the contrast agent and filling the intestinal lumen with a negative contrast agent, as well as SRI, are methods that enable the monitoring of the disease and assessment of the response to therapy [p. 79–110].

Minimal consensus statement on imaging and endoscopic examinations:

To locate the primary tumour site and assess the stage of advancement, SRI in correlation with multiphase CT/MRI is recommended (*evidence level 3).

— CT/MRI enterography, CT/MRI enteroclysis, or endoscopic techniques may be required to locate the primary tumour site (*evidence level 3).

— Colonoscopy and assessment of the terminal section of the ileum to detect the primary lesion and to exclude a concomitant neoplastic disease (colon cancer) (*evidence level 4).

3.3. Pathomorphological diagnostics

3.3.1. NENs of the small intestine

Neuroendocrine tumours of the small intestine differ from other gastro-entero-pancreatic NETs, as they originate exclusively from serotonin-producing cells. Most are well-differentiated and demonstrate low proliferative activity. Therefore, their growth is slow and associated with slowly increasing, non-specific clinical symptoms. Thus, most of them are diagnosed as a regional, advanced disease. The diagnostics of small intestine NENs, due to their specific clinical course, is frequently based on the assessment of the material from a large-core needle biopsy of the tumour (or its hepatic metastases), which is often the first clinical symptom, or examination of the small intestine material removed due to obstruction, along with the previously undiagnosed tumour.

3.3.1.1. Diagnostic algorithm

Histopathological reporting is still the basis for the diagnosis of neuroendocrine tumours, as well as for other solid neoplasms. Histopathological type and stage of advancement according to the current standards enable the application of therapeutic management according to the current state of knowledge [4].
Macroscopic assessment of small intestinal NENs in post-surgical material

Procedures included in the Standards of the Polish Society of Pathologists should be followed during preparation of the post-surgical material from the removed small intestinal tumour [68].

1. The tumour location, considering the length of the intestinal section obtained for examination, the tumour relation to the intestine resection margins, and the width of the removed intestinal mesentry.

2. Tumour size, preferably in three dimensions. In the case of numerous lesions, their size, mutual relation, and resection margins should be provided. Relation of the tumour(s) to the layers of the intestinal and mesenteric wall.

3. Presence and size of the mesenteric lymph nodes.

4. Other pathological lesions in the assessed material.

Microscopic assessment on NENs:

The histopathological assessment is based on the WHO 2017 [69] classification and [69] ENETS 2016 guidelines [4,32] together with the AJCC 8th edition from 2017 [70]. As in other sections of the gastrointestinal tract, NENs are classified as neuroendocrine well-differentiated neoplasms: NETs G1 with Ki-67 index below 3% and NETs G2 with Ki-67 between 3% and 20%, and NEC, which include NETs G3 and neuroendocrine carcinomas: large- or small-cell NEC, and MiNEN (mixed endocrine non-endocrine neoplasms).

The diagnostic criteria are discussed in Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (p. 79–110). Histopathological assessment should include:

1. Histopathological type of the NEN according to the WHO 2017 classification, completed with Chapter 2.2 and Table VII.

2. The histological grading (G) according to ENETS/WHO 2017.

3. Assessment of the immunohistochemical expression of neuroendocrine markers: chromogranin A and synaptophysin, as well as Ki-67/MIB1 proliferative activity (as described below) according to the procedure described in the general section – obligatory [32, 71, 72].

4. Pathomorphological pTNM staging according to ENETS and AJCC/UICC — obligatory — Table I. Assessment of clinical staging conditional — Table II [4].

5. Assessment of other immunohistochemical markers, such as NSE, CD56, CDX2, serotonin, somatostatin receptors — conditional [4].

A minimal histopathological report on small intestinal NEN should include:

— Histological type of the neoplasm according to the WHO classification, considering the division into well-differentiated neuroendocrine neoplasms (NETs G1 and NETs G2) with Ki-67 index below 20%, and NETs G3 and neuroendocrine carcinomas (NECs) with Ki-67 index above 20% or mixed neoplasms (MiNEN).

— Histological G grading, referring to well-differentiated neoplasms (NETs G1, NETs G2, NETs G3).

— pTNM histopathological staging according to ENETS and AJCC/UICC classifications (it is important to provide the affiliation of the classification in each case);

— Assessment of surgical margins.

— The histopathological diagnosis of NEN must be confirmed by immunohistochemical tests assessing the expression of the neuroendocrine markers: synaptophysin and chromogranin A, as well as Ki-67 proliferative activity using the MIB1 antigen.

Recent TNM UICC 2017 classification [72] divides metastases to lymph nodes into N1: metastases present in less than 12 lymph nodes, of ≤ 2 cm, and N2: metastases present in 12 or more lymph nodes and/or presence of a metastases of > 2 cm.

The classification of distant metastases also changes. Metastases (feature M1) is divided into three groups.

<table>
<thead>
<tr>
<th>Feature T – primary tumour x</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
<td>The tumour has not been assessed</td>
</tr>
<tr>
<td>T0</td>
<td>No evidence of a primary tumour</td>
</tr>
<tr>
<td>T1</td>
<td>Tumour invades the lamina propria or submucosa and is ≤ 1 cm</td>
</tr>
<tr>
<td>T2</td>
<td>Tumour invades the muscularis propria and/or is &gt; 1 cm</td>
</tr>
<tr>
<td>T3</td>
<td>Tumour penetrates the muscularis propria and invades the subserosal tissue, without serosal invasion</td>
</tr>
<tr>
<td>T4</td>
<td>Tumour invades the peritoneum, other organs, or adjacent structures</td>
</tr>
</tbody>
</table>

N — regional lymph nodes

NX Lymph nodes have not been assessed

N0 No regional lymph node metastases

N1 Regional lymph node metastases

M — distant metastases

MX Distant metastases cannot be assessed

M0 No distant metastases

M1 Distant metastases

Note: If more than one tumour is present, we add “m” to the letter T, regardless of the size. xx If there is evidence of distant metastasis, the anatomical site should be specified in the brackets as follows: PUL for pulmonary, HEP for hepatic, and OSS for osseous.
M1a Only hepatic metastases,
M1b Extra-hepatic metastases,
M1c Both hepatic and extra-hepatic metastases.
Clinical staging of NENs of the small intestine according to ENETS is presented in Table II [4].
A slightly less developed clinical staging according to AJCC/UICC 2017 is presented for comparison [71, 72] (Table III).

### 3.3.2. Neuroendocrine neoplasms of the appendix

**Pathogenesis**
Most NENs of the appendix are detected during surgery due to acute inflammation of the organ.

Well-differentiated NENs are mostly found in the terminal part of the appendix (75%), less frequently in the middle part (15%) and in the proximal margin (10%). Macroscopically, they form hard, whitish-yellow, not encapsulated nodules, with an expanding growth margin, whereas MiNEN tumours, including goblet cell carcinoid, are white, sometimes mucous, of 1–5 cm in diameter (mean diameter of 2 cm), and show an infiltrative growth pattern. These neoplasms are malignant; they are classified and treated like classical adenocarcinomas of the appendix [3].

**3.3.2.1. Diagnostic algorithm**
Contrary to the NENs of the jejunum and ileum, for which a similar consensus was developed regarding the assessment of the T-staging, two classifications are recommended for the NENs of the appendix: one by the European Neuroendocrine Tumour Society (ENETS) and the other by the American associations: American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC). It is recommended that both classifications are used. Firstly, because presently there is no evidence in favour of the usefulness of either of them, and secondly, because in cases raising doubts as to the scope of therapeutic management on the basis of one classification, the use of the other one could resolve the doubts [3].

---

**Table II. Small intestinal NENs staging [4]**

<table>
<thead>
<tr>
<th>Stage</th>
<th>T feature</th>
<th>N feature</th>
<th>M feature</th>
<th>Advancement</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Tis</td>
<td>N0</td>
<td>M0</td>
<td>Local neoplasm</td>
</tr>
<tr>
<td>I</td>
<td>T1</td>
<td>N0</td>
<td>M0</td>
<td>Local neoplasm</td>
</tr>
<tr>
<td>IIA</td>
<td>T2</td>
<td>N0</td>
<td>M0</td>
<td>Local neoplasm</td>
</tr>
<tr>
<td>IIIB</td>
<td>T3</td>
<td>N0</td>
<td>M0</td>
<td>Local neoplasm</td>
</tr>
<tr>
<td>IIIA</td>
<td>T4</td>
<td>N0</td>
<td>M0</td>
<td>Local neoplasm</td>
</tr>
<tr>
<td>IIIB</td>
<td>T1-T4</td>
<td>N1</td>
<td>M0</td>
<td>Regional neoplasm</td>
</tr>
<tr>
<td>IV</td>
<td>T1-T4</td>
<td>any</td>
<td>M1</td>
<td>Generalised neoplasm</td>
</tr>
</tbody>
</table>

**Macroscopic assessment of NENs of the appendix.**
A relatively low incidence of NENs of the appendix should always be a reason for very careful macroscopic examination and careful sample collection. Procedures included in the Standards of the Polish Society of Pathologists should be followed during the preparation of the post-surgical material from the removed small intestinal tumour [68]. The samples should be collected from the end of the appendix, its middle part, and base (the proximal colonic margin), and the size of the tumour should be stated.

The macroscopic description should include the following:
- The length of the appendix obtained for examination, with a description of the tumour location relative to the resection margin.
- Tumour assessment: the size in three dimensions, and cross-section appearance.
- Condition of the serosa and mesoappendix at the tumour site — it is necessary to collect numerous samples.

**Table III. AJCC/UICC 2017 staging classification for NENs [71, 72]**

<table>
<thead>
<tr>
<th>Clinical stage</th>
<th>T feature</th>
<th>N feature</th>
<th>M feature</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage I</td>
<td>T1</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage II</td>
<td>T2, T3</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage III</td>
<td>T4</td>
<td>Any N</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IV</td>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
</tr>
</tbody>
</table>

**Microscopic assessment of NENs of the appendix:***
1. Histological type of NEN according to the 2017 WHO classification [3, 69] completed with information from Chapter 2.2 and Table VII.
2. The histological grading (G) according to ENETS [3, 32].
3. Assessment of immunohistochemical expression of neuroendocrine markers: chromogranin A and synaptophysin, as well the Ki-67/MIB1 proliferative activity, is obligatory. Immunohistochemical assessment of NSE, CD56, CDX2 markers, and serotonin is recommended conditionally, in the case of metastatic differentiation, especially if the original site of the neoplasm is unknown. A positive reaction with CDX2 and/or serotonin indicates an intestinal, particularly ileocaecal, origin of the neoplasm [3].
4. The ENETS [32] and AJCC/UICC [71, 72] histopathological staging regarding the T-feature of NENs of the appendix is presented in Table IV [32, 71, 72].
Prognostic factors for NENs of the appendix

Tumour size and infiltration of the mesoappendix are important risk factors of NENs of the appendix. According to European and American guidelines, they form the criteria for division into pTNM classification stages. According to a report by the College of American Pathologists, cases in which the diameter of the tumour is above 1 cm and below 2 cm, where infiltration of the mesoappendix is present, should be treated as those having an uncertain prognosis. Potentially benign tumours are smaller than 1 cm and do not invade the mesoappendix. It is worth emphasising that, according to the pTNM 2010 classification, NECs of the appendix and MANECs composed of classical and neuroendocrine carcinoma components, as well as goblet-cell carcinoids, are diagnosed following the criteria for classical carcinomas, and not those for NENs.

Apart from the above features, the histopathological report should include the assessment of margins: proximal, distal, mesoappendiceal, and radial, as well as the angioinvasion of blood vessels. It should be noted that it is necessary to examine the colonic proximal margin because invasion of the caecum/colon determines the treatment method. During the assessment of the slides, particular attention should also be paid to any small periserosal vessels, which could be ignored, especially if the samples from the periphery of the tumour were inadequately collected [3].

UICC 2017 classification system, as was the case with the small intestine, differentiates metastases (M1) from the appendix in the following manner:
- M1a Only hepatic metastases,
- M1b Extra-hepatic metastases,
- M1c Both hepatic and extra-hepatic metastases.

Clinical advancement stage according to the same classification system for the appendix is almost identical as for the small intestine. The only difference regards features N1 and N2, dependant on the number and weight of the metastases, which are not considered during the assessment of lymph node metastases, but only the presence of N1 metastasis is reported [72].

Minimal consensus statement on pathomorphological examination:
- Minimal histopathological report on NENs of the small intestine and the appendix should include:
  - Histological type of the neoplasm according to the WHO classification, considering the division into well-differentiated neuroendocrine neoplasms (NEN) and neuroendocrine carcinomas (NEC) or mixed neoplasms (MiNEN);
  - Histological G grading referring to well-differentiated neoplasms (NEN G1, NEN G2);
  - pTNM histopathological staging according to ENETS and AJCC/UICC classifications (it is important to provide affiliation of the classification in each case);
Assessment of surgical margins.

The histopathological diagnosis of NEN must be confirmed by immunohistochemical tests assessing expression of the neuroendocrine markers: synaptophysin and chromogranin A, as well as Ki-67 proliferative activity using the MIB1 antigen.

4. Treatment

4.1. Surgical treatment

NENs of the midgut are usually located in the distal part of the small intestine or in the appendix. They frequently present in a multi-focal form, with concurrent hepatic metastases [3, 73]. The preferred treatment of intestinal NENs is partial or multiple resection with lymphadenectomy, as a radical treatment, or palliative, cytoreductive surgery reducing the tumour mass by approximately 90% [3]. If possible, the primary tumour site should be removed, even if the disease is generalised, with concurrent resection or enucleation of the hepatic metastatic lesions [74].

Treatment of aNENs depends primarily on the tumour size and the intensity of infiltration of the primary tumour [75–77]. The indications for right-sided hemicolectomy are the following tumour features:

1. Diameter of more than 2 cm, aNEN G1/G2 (NET classified as at least T3 (ENETS) or T2 (UICC/AJCC) [5, 13, 78–82];
2. Location at the base of the appendix (although there is no evidence for a poorer prognosis, and in such cases a higher incidence of complications should always be considered, compared to simple appendectomy) [79, 83–86];
3. Mesoappendical invasion, MAI (there is no evidence of a correlation between the tumour size and MAI, which questions the ENETS arbitrary infiltration depth of 3 mm as a border between T2 < 3 mm and T3 > 3 mm) [5];

*Performance of SRI depends on the experience and choice of the treating centre; there is no evidence of the effectiveness or necessity for this diagnostic management

**Patients who cannot be operated on due to concurrent diseases, or who do not give consent to a surgical treatment

Figure 1. Algorithm of therapeutic management and monitoring of neuroendocrine tumours of the appendix found accidentally during appendectomy due to acute appendicitis or another gynaecological or surgical procedure in the abdominal cavity [75] aNENs — neuroendocrine neoplasm of the appendix; MAI — mesoappendiceal infiltration; MRI — magnetic resonance; NEN — neuroendocrine neoplasm; SRI — somatostatin receptor imaging; US — ultrasonography

...
Patients with carcinoid heart disease require care.

Surgical treatment of the midgut tumours involves the resection, thermoablation, chemoembolisation [5, 80, 81, 86];

G2 feature according to WHO [87];

V1 neuro- and angioinvasion, L1 infiltration of lymph nodes — increase the risk of metastases to the lymph nodes [82];

Goblet cell carcinoid, MiNEN and NEC G3 are not classified as NEN; they should be treated according to the recommendations regarding adenocarcinoma [5, 32, 71, 76];

In NENs of the appendix with hepatic metastases, the recommended management is right-sided hemicolectomy including removal of the metastases (anatomical and non-anatomical resections) [74].

In the case of multiple metastases, a palliative surgery removing the metastases should be considered (resection, thermoablation, chemoembolisation) [5, 32] (Fig. 1).

**Minimal consensus statement on surgical treatment:**

- Surgical treatment of the midgut tumours involves the complete removal of the tumour within the healthy tissue, together with the lymph nodes (*evidence level 3*).
- In palliative treatment, cytoreductive management should be considered (*evidence level 3*).
- In tumours of the appendix of < 2 cm, without any risk factors, appendectomy should be performed.
- In tumours of > 2 cm and more advanced tumours, right-sided hemicolectomy should be performed (*evidence level 3*).

**4.2. Symptomatic pharmacological treatment**

**4.2.1. Symptomatic treatment in carcinoid syndrome**

- Long-acting somatostatin analogues: octreotide LAR (10–30 mg i.m. every four weeks, but the lowest dose is rarely used), lanreotide Autogel (60–120 mg s.c. every 4–6 weeks, but the lowest dose is rarely used) are the gold standards in the treatment of carcinoid syndrome (see p. 79–110) [88, 89, 90, 91]. Radioisotope imaging of somatostatin receptors is not required before the SSA treatment.
- If the symptom control is not satisfactory during standard treatment with long-acting somatostatin analogues, the following should be considered: reducing the interval between injections, increasing the dose of SSA, and/or adding a short-acting SSA (octreotide, solution for injections 100 μg/amp).
- In the case of resistance to SSA, in some patients a new SSA (pasireotide) is found to be effective [92]. Moreover, a new drug inhibiting the biosynthesis of serotonin, telotristat (LX1032), is presently being studied in clinical trials in patients with carcinoid syndrome [93, 94].
- The symptomatic treatment of patients with carcinoid syndrome also involves loperamide, ondansetron, and pancreatic enzymes, or group B vitamins in case of deficiency [23].
- Patients with carcinoid heart disease require care in referential cardiological and cardio-surgical centres [27].

**4.2.2. Carcinoid crisis treatment**

- There are no clear EBM recommendations for the management of carcinoid crisis [3].
- The soonest possible introduction of somatostatin analogue therapy is of the greatest importance; a short-acting SSA in high doses is usually administered intravenously (octreotide: 25–500 μg/h IV; on average 100–200 μg/h IV) [30]. In carcinoid crisis (particularly in NENs of the foregut), the administration of glucocorticoids and antihistamines may be considered.
- It is necessary to introduce intensive symptomatic treatment of dehydration, acute renal failure, hypercalcaemia, arterial hypertension or hypotonia, cardiac failure, and infection [3].

**4.2.3. Preparation of patients with NETs of the small intestine and the appendix for surgery**

- There are no clear recommendations for the preparation of patients with NENs of the small intestine and appendix for surgery [95].
- In patients with carcinoid syndrome, pre-operative administration of short-acting SSA should be considered, regardless of the long-acting SSA therapy (e.g. octreotide 200–300 μg s.c. before the surgery and/or continuous infusion of 50–100 μg/hour intraoperatively and/or 24–48 hours after the surgery) [3]. Cardiological consultation should be considered before the surgery.
- In patients with hormonally non-active NENs, it is recommended that a short-acting SSA should be available during the operation, and administered in the case of an unstable haemodynamic condition [3].

**4.3. Systemic treatment of small intestinal NENs in the generalised period**

**4.3.1. Long-acting somatostatin analogues**

- Long-acting somatostatin analogues: octreotide LAR (30 mg i.m. every four weeks), lanreotide Autogel (120 mg s.c. every four weeks) are first-line therapies to stabilise neoplastic disease in patients.
with well-differentiated NETs of the small intestine in the generalised period (see p. 79–110) [96, 97].

4.3.2. Peptide Receptor Radionuclide Therapy with radioisotope-labelled somatostatin analogues (PRRT)

— In patients with metastatic NETs of the small intestine with a high expression of somatostatin receptors, in progression during the SSA treatment, therapy with radioisotope-labelled somatostatin analogues should be considered as the first-line treatment [98]. Qualification and treatment should follow the principles described in "Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms" (p. 79–110).

— In patients with negative receptor scintigraphy and evidence of $^{131}$I-MIBG accumulation in the tumour or metastases, therapy with $^{131}$I-MIBG may be considered [99].

4.3.3. Targeted therapies — everolimus

Everolimus therapy is effective in patients with hormonally non-active, well-differentiated gastro-entero-pancreatic NETs, including small intestinal NETs, in the generalised period [100]. Everolimus may be considered in patients with generalised progressing NETs of the small intestine following ineffective SSA treatment, and when other treatment methods (including PRRT) are ineffective or cannot be applied. In Poland everolimus therapy for this indication is non-refundable.

4.3.4. Chemotherapy

Due to limited effectiveness, chemotherapy is not recommended as the first-line treatment in patients with well-differentiated, metastatic neuroendocrine tumours of the small intestine. It is used exclusively in advanced small intestinal NETs, when other treatment methods appear ineffective. CAPTEM (temozolomide + capecitabine) may be considered, on the basis of small, prospective, phase II studies involving small groups of patients [101–103]. The principles of chemotherapy have been described in "Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms" (p. 79–110).

Goblet cell carcinoma (GCC)

Goblet cell carcinoids of the appendix constitute a specific form of neuroendocrine neoplasms of the appendix. These rare and aggressive neoplasms comprise both glandular and neuroendocrine components, and their course is aggressive [104, 105].

Adjuvant chemotherapy – qualification according to the same principles as in cancer of the large intestine: FOLFOX is recommended in stage III (pT3, pT4, N+), although there are no reports from randomised studies, only scientific reports from individual centres [5, 106].

In the case of a diffused neoplasm, or recurrence after a radical treatment, due to a similar course of disease to glandular cancer of the large intestine, the same chemotherapy regimens are recommended (FOLFOX, FOLFIRI). Hyperthermic intraperitoneal chemoperfusion using mitomycin (HIPEC) and systemic chemotherapy, as well as surgical cytoreduction, may improve the prognosis in patients with diffused or recurrent GCC in the peritoneum [107, 108].

Minimal consensus statement on pharmacological and radioisotope treatment of NENs of the small intestine and the appendix

Long-acting SSA are the treatment of choice in case of hormonally active small intestinal NETs (carcinoid syndrome and carcinoid crisis) (evidence level 1) [109].

In the case of small intestinal NETs in the generalised period (hormonally active and non-active), long-acting SSA should be used (antiproliferative effect) (evidence level 1).

In patients with generalised NENs of the small intestine in progression during the SSA treatment, and with a good expression of somatostatin receptors, radioisotope therapy should be the first-line treatment (evidence level 1), and targeted therapies should be considered afterwards — everolimus (evidence level 1). In patients with a low expression of somatostatin receptors, targeted therapy is indicated.

When the above therapies are exhausted, in certain cases chemotherapy may be considered (evidence level 4).

5. Monitoring

Determination of CgA and 5-HIAA may be useful for the assessment of treatment and its effectiveness in patients with carcinoid symptoms. In patients treated with SSA, lower excretion of 5-HIAA and decreased levels of chromogranin A are associated with reduced intensity and frequency of clinical symptoms (flushing, diarrhoea). However, it is believed that 5-HIAA excretion does not reflect the progression or the response to treatment as precisely as the monitoring of CgA concentration. A high association (80%) between changes in the tumour size and concentration of chromogranin A has been observed. An even higher association (88%) was found in a group of patients with non-secreting tumours, in whom other markers could not be used [2, 3, 34]. However, in certain patients a very good clinical response to the treatment of carcinoid syndrome with SSA was observed, without reduced CgA levels [3].

The frequency of follow-up examinations depends on NEN differentiation and staging, as well as on the introduced treatment (see p. 79–110). The physical
examination and additional tests (three-phase CT scanning of the abdominal cavity and radioisotope imaging of somatostatin receptor SRI), as well as biochemical indicators (CgA and 5-HIAA), should be monitored. After a radical surgery: in patients with NET G1 and G2 every 6–12 months. In the case of a residual tumour or metastases: in patients with NET G1-G2, every 3–6 months. In G3, NEC: every 2–3 months [110].

In patients with carcinoid heart disease, echocardiographic examination and NT-proBNP assessment should be repeated at least every 12 months. If the disease progresses, follow-up imaging and biochemical tests need to be conducted more frequently — every three months [38, 110].

**Minimal consensus statement on follow-up:**

Monitoring of the disease and treatment should be planned individually for each patient, considering the clinical picture, grading, and staging of the disease, and its treatment.

In well-differentiated aNETs with a maximum tumour size < 1 cm and resection status (R0), further follow-up is not required. Patients with NET-G1 should be assessed every 6–12 months, with NET-G2, every 3–6 months, and with NEN-G3, every 3 months.

Minimal examination includes: CgA, 5-HIAA (in certain cases) and triphasic CT, as well as radioisotopes somatostatin receptor imaging (SRI): echocardiographic examination and NT-proBNP every 6–12 months in patients with carcinoid heart disease.

### References

16. Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the di...


WHO Classification of Tumours of the Digestive System. IARC 2017 (in press)


Neuroendocrine neoplasms of the small intestine and appendix — management guidelines

Bednarczuk Tomasz et al.